Swedbank AB Raises Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Swedbank AB lifted its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 4.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 564,381 shares of the medical research company's stock after acquiring an additional 25,482 shares during the quarter. Swedbank AB owned approximately 0.10% of Amgen worth $147,100,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of AMGN. Cadinha & Co. LLC grew its holdings in Amgen by 0.6% in the third quarter. Cadinha & Co. LLC now owns 5,209 shares of the medical research company's stock worth $1,678,000 after purchasing an additional 32 shares during the period. Lansing Street Advisors grew its stake in shares of Amgen by 1.3% in the 3rd quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company's stock worth $832,000 after buying an additional 32 shares during the last quarter. Unionview LLC increased its position in Amgen by 3.8% during the 3rd quarter. Unionview LLC now owns 876 shares of the medical research company's stock valued at $282,000 after buying an additional 32 shares in the last quarter. Traveka Wealth LLC raised its stake in Amgen by 4.3% during the third quarter. Traveka Wealth LLC now owns 807 shares of the medical research company's stock valued at $260,000 after buying an additional 33 shares during the last quarter. Finally, AM Investment Strategies LLC boosted its holdings in Amgen by 0.4% in the third quarter. AM Investment Strategies LLC now owns 7,471 shares of the medical research company's stock worth $2,407,000 after acquiring an additional 33 shares in the last quarter. Institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

NASDAQ AMGN traded up $2.34 on Thursday, reaching $284.02. 2,555,228 shares of the stock were exchanged, compared to its average volume of 3,025,703. The firm has a market capitalization of $152.67 billion, a PE ratio of 36.37, a PEG ratio of 2.78 and a beta of 0.56. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company's 50-day simple moving average is $271.35 and its two-hundred day simple moving average is $304.99. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts' consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company had revenue of $8.50 billion for the quarter, compared to analysts' expectations of $8.50 billion. During the same quarter in the previous year, the company earned $4.96 EPS. Amgen's revenue for the quarter was up 23.2% on a year-over-year basis. Analysts expect that Amgen Inc. will post 19.56 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.35%. This is an increase from Amgen's previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen's payout ratio is presently 115.24%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wolfe Research started coverage on Amgen in a research report on Friday, November 15th. They issued a "peer perform" rating for the company. Redburn Partners dropped their target price on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Piper Sandler Companies reissued an "overweight" rating and set a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. William Blair reaffirmed an "outperform" rating on shares of Amgen in a research report on Tuesday, November 12th. Finally, Leerink Partners reduced their target price on Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, Amgen has an average rating of "Hold" and a consensus target price of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.